Shantha Biotechnics awarded large vaccine contracts by United Nations agency

Shantha awarded 2010-2012 contracts for pentavalent vaccine SHAN5™ (DTP, HiB, Hep.B)

03-Sep-2009 - France

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that Shantha Biotechnics was awarded contracts by a United Nations agency for supplies of pentavalent vaccine SHAN5™ (combination vaccine of diphtheria, pertussis, tetanus, Haemophilus influenza B, and Hepatitis B). The contracts, worth $340 million, cover the period 2010-2012.

Sanofi Pasteur, through its existing and new contracts, now provides a full range of vaccines used within the Expanded Program on Immunization (EPI) of the World Health Organization (WHO).

Commenting on the contracts, Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur, said: “These awarded contracts underline Shantha Biotechnics’ high expertise and the quality of their state-of-the-art manufacturing facilities. While Shantha Biotechnics is joining the sanofi-aventis Group, those contracts perfectly illustrate our ambition to provide the best vaccines at affordable prices to many people around the world.”

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...